title: Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2.
abstract: Autoimmune hepatitis (AIH) is a disease of unknown etiology, characterized by liver-related autoantibodies. Autoimmune hepatitis is subdivided into two major types: AIH type 1 is characterized by the detection of ANA, SMA, ANCA, anti-ASGP-R, and anti-SLA/LP. Autoimmune hepatitis type 2 is characterized to be mainly related with drug-metabolizing enzymes as autoantigens, such as anti-LKM (liver-kidney microsomal antigen)-1 against CYP2D6, anti-LKM-2 against CYP2C9-tienilic acid, anti-LKM-3 against UGT1A, and anti-LC1 (liver cytosol antigen)-1 and anti-APS (autoimmune polyglandular syndrome type-1) against CYP1A2, CYP2A6, and others. Anti-LKM-1 sera inhibited CYP2D6 activity in vitro but did not inhibit cellular drug metabolism in vivo. CYP2D6 is the major target autoantigen of LKM-1 and expressed on plasma membrane (PM) of hepatocytes, suggesting a pathogenic role for anti-LKM-1 in liver injury as a trigger. Anti-CYP1A2 was observed in dihydralazine-induced hepatitis, and radiolabeled CYP1A2 disappeared from the PM with a half-life of less than 30 min, whereas microsomal CYP1A2 was stably radiolabeled for several hours. Main antigenic epitopes on CYP2D6 are aa 193-212, aa 257-269, and aa 321-351; and D263 is essential. The third epitope is located on the surface of the protein CYP2D6 and displays a hydrophobic patch that is situated between an aromatic residue (W316) and histidine (H326). Some drugs such as anticonvulsants (phenobarbital, phenytoin, and carbamazepine) and halothane are suggested to induce hepatitis with anti-CYP3A and anti-CYP2E1, respectively. Autoantibodies against CYP11A1, CYP17, and/or CYP21 involved in the synthesis of steroid hormones are also detected in patients with adrenal failure, gonadal failure, and/or Addison disease.
authors.affiliation: Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan. mizutani@phar.nagoya-cu.ac.jp
authors.forename: Takaharu
authors.initials: T
authors.lastname: Mizutani
authors.forename: Masakazu
authors.initials: M
authors.lastname: Shinoda
authors.forename: Yuta
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Takuya
authors.initials: T
authors.lastname: Kuno
authors.forename: Asuka
authors.initials: A
authors.lastname: Hattori
authors.forename: Toru
authors.initials: T
authors.lastname: Usui
authors.forename: Nayumi
authors.initials: N
authors.lastname: Kuno
authors.forename: Takashi
authors.initials: T
authors.lastname: Osaka
mesh_terms: D000818:Animals; D001323:Autoantibodies / Q000276:immunology*; D019389:Cytochrome P-450 CYP2D6 / Q000276:immunology*; D003577:Cytochrome P-450 Enzyme System / Q000276:immunology; D019693:Hepatitis, Autoimmune / Q000201:enzymology / Q000276:immunology*; D006801:Humans; D008658:Inactivation, Metabolic / Q000276:immunology
chemical_list: D001323:Autoantibodies; D003577:Cytochrome P-450 Enzyme System; D019389:Cytochrome P-450 CYP2D6